Equity Overview
Price & Market Data
Price: $1.61
Daily Change: $0.00 / 0.00%
Range: $1.53 - $1.69
Market Cap: $52,471,304
Volume: 72,255
Performance Metrics
1 Week: 30.15%
1 Month: 6.02%
3 Months: -17.90%
6 Months: -81.64%
1 Year: -85.94%
YTD: -57.76%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.